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INTRODUCTION
The prevalence of allergic diseases has been increasing world-
wide. Bronchial asthma (BA) is a chronic inflammatory air-
way allergic disease. There are some objective biomarkers to 
diagnose asthma and to assess its severity, including forced 
expiratory volume in one second (FEV1), FEV1/forced vital ca-
pacity (FVC), fraction of exhaled nitric oxide, and sputum eo-
sinophil and neutrophil counts.1-4 Other new markers, such as 
YKL-40 and clusterin, have recently received attention.5,6 How-
ever, evaluation of these parameters requires a patient to blow 
into a machine or to expectorate sputum. Due to the nature of 
asthma, many patients cannot perform these tests because of 
shortness of breath, absence of sputum, and non-compliance. 
In addition, allergic rhinitis (AR) and chronic spontaneous 
urticaria (CSU) have few biomarkers to diagnosis and evalu-
ate their severity. Therefore, it is necessary to identify suitable 
serologic biomarkers of inflammation that may be easily eval-
uated in patients with allergic diseases. 
CD93 is a cell surface protein that belongs to the newly dis-
covered IXV family of transmembrane glycoproteins.7 CD93 is 
expressed on various cells involved in the inflammatory cas-
cade and hematopoiesis. While CD93 was originally described 
as a complement 1q receptor that enhances phagocytosis and 
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as a marker of developing B cells, CD93 is now recognized to 
be required for phagocytosis and immunity and to function as 
a novel regulator of inflammation.8-10 Nonetheless, the molec-
ular function of CD93 is still unknown. The regulatory role of 
CD93 in inflammation has been studied in various diseases. 
Soluble CD93 (sCD93) levels were significantly increased in 
the synovial fluid of rheumatoid arthritis patients.11 sCD93 ex-
pression in patients with systemic lupus erythematosus (SLE) 
is inversely correlated with prednisone dose.12 Overall, CD93 
seems to be a therapeutic marker for inflammation, as serum 
levels are elevated during inflammation and decline following 
anti-inflammatory treatment. However, the clinical signifi-
cance of serum sCD93 in allergic diseases, such as AR, CSU, 
and BA, has not been well studied. 
We aimed to elucidate the clinical diagnostic value of sCD93 
in various allergic diseases and to determine the suitability of 
sCD93 as a novel diagnostic and therapeutic biomarker.
MATERIALS AND METHODS
Patients
We enrolled 414 subjects who were diagnosed with allergic 
diseases (at least one of these: AR, CSU, and BA) at the Allergy 
Asthma Center of the Severance Hospital in Seoul, Korea from 
May 2014 to September 2015. Among these subjects, 41 were 
excluded {15: recent severe allergic reaction, anaphylaxis; 19: 
ongoing immunotherapy dose-up; 4: activated status of another 
inflammatory disease [2: atopic dermatitis (AD); 1: rheumatoid 
arthritis, 1: Behcet’s disease]; 3: severe cutaneous adverse drug 
reaction [2: toxic epidermal necrolysis, 1: Stevens-Johnson 
syndrome]}. Additionally, 25 patients refused the study. The 
348 subjects enrolled in the cross sectional study were patients 
over the age of 19 who were admitted to one of the study clinics, 
were diagnosed with allergic diseases, and agreed to partici-
pate in this study, including submitting to all basic tests and 
the sCD93 blood test (Fig. 1). 
Among the 348 patients, we selected steroid-naïve patients 
who were first diagnosed with BA at this visit and who required 
inhaled corticosteroid (ICS) treatment to define the effects of 
steroids on serum sCD93. A total of 313 patients were not eligi-
ble for the cohort study, because they were not diagnosed with 
BA, did not require ICS treatment, or were already using a ste-
roid-containing inhaler. Fourteen patients who were eligible 
for the cohort study refused participation in this study, and 7 
patients who agreed to participate were lost to follow-up. The 
14 patients enrolled in the cohort study, which was serially fol-
lowed-up, were treated with ICS, and their serum sCD93 levels 
were assessed after 4 or 8 weeks of ICS use (Fig. 1). They were 
prescribed by the low- or medium-dose of ICS according to the 
doctor’s judgment.
BA was diagnosed by an allergy specialist based on clinical 
guidelines using a bronchodilator test and/or bronchial prov-
ocation test.13 AR,14 allergic conjunctivitis,15 AD,16 and CSU17 
were diagnosed based on international guidelines. No systemic 
steroids therapy in past 8 weeks was given in AR, BA, and CSU 
groups.
This study was approved by the Institutional Review Board 
of Yonsei University College of Medicine (approval number: 
4-2013-0397). All enrolled patients provided written informed 
consent.
Basic tests
All 348 patients enrolled in the cross sectional study underwent 
basic tests, including blood and sputum tests and a lung func-
tion test. The blood collection in exacerbated group was per-
formed before steroids uses. First, a complete blood count was 
performed using an automated analyzer to determine blood 
eosinophil and neutrophil counts. Next, the eosinophil and 
neutrophil percentages in induced sputum were measured. 
The obtained sputum was centrifuged, and the supernatant 
was collected. Samples were diluted in phosphate-buffered sa-
line and centrifuged at 450 rpm for 6 min to prepare cytology 
slides. After staining the slides with Wright’s stain, a differen-
tial count was performed using a light microscope as reported 
previously.5 Lastly, FEV1 and FEV1/FVC were evaluated by pul-
monary function test using commercially available equipment 
(MS-IOS; Masterlab-IOS, Jaeger, Wurzburg, Germany). All of 
these tests were conducted within 1 week of the date of blood 
collection for sCD93 measurement. The 14 patients who were 
enrolled in the cohort study were subjected to a repeat of all 
the tests, including a serum sCD93 level test, after 4 weeks or 8 
weeks of ICS use. ICS was prescribed by an allergy specialist. 
Fig. 1. Flow diagram of study subjects.
414 patients were screened for the study
41 patients were excluded
– 15: recent severe allergic reaction (e.g., anaphylaxis)
– 19: ongoing immunotherapy dose-up schedule
– 4: active status of other inflammatory disease
– 3: severe cutaneous adverse drug reaction
334 patients were excluded
– 313: not eligible for cohort study
– 14: refused the cohort study
– 7: follow up loss
373 patients were eligible for the study
25 patients refused the study
348 patients were enrolled for case-control study
14 patients were enrolled for cohort study
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Serum preparation and sCD93 measurement
Blood samples were collected from all of the study participants 
and were centrifuged for 10 minutes at 3000 rpm at 15°C. The 
sCD93 levels in the supernatants (serum) were estimated using 
an enzyme-linked immunosorbent assay kit (Affymetrix eBio-
science, Vienna, Austria) according to the manufacturer’s in-
structions. The detection range for sCD93 was 3.3–400 ng/mL. 
All samples were measured in duplicate, and the results were 
expressed as ng/mL in serum.
Definition of clinical parameters 
Exacerbated allergic disease was defined as acute aggravation 
of allergic disease symptoms requiring increases or other 
changes in the medication regimen to relieve aggravated 
symptoms [exacerbated AR (eAR): sneezing, rhinorrhea, and 
nasal obstruction; exacerbated CSU (eCSU): number of hives 
and pruritus; exacerbated BA (eBA): cough, chest tightness, 
and dyspnea]. Stable allergic disease was defined by a stable 
status of the allergic disease, without any aggravated symp-
toms requiring changes in the medication regimen [stable AR 
(sAR); stable CSU (sCSU); stable BA (sBA)]. 
The dose of ICS use was assessed within 1 week of the date 
of blood collection for sCD93 measurement. Study partici-
pants were categorized according to ICS use as non-users, 
low-dose users, medium-dose users, and high-dose users 
based on the Global Initiative for Asthma guidelines.18 
 
Statistical analysis
The levels of sCD93 were normally distributed, as defined by 
the Kolmogorov-Smirnov and Shapiro-Wilk tests. Then, we 
used the two-sample t-test (independent sample t-test) and 
analysis of variance, followed by a post-hoc Bonferroni test, to 
compare the sCD93 levels among the subgroups, including 
the comparison of serial sCD93 levels in steroid-naïve pa-
tients. Pearson’s correlation was used to define the correlation 
between sCD93 levels and the assessed parameters. All statis-
tical analyses were performed with SAS version 9.2 (SAS Insti-
tute Inc., Cary, NC, USA), and significance was defined as 
p<0.05.
RESULTS
Clinical characteristics of cross sectional study 
subjects
The mean age of the 348 subjects enrolled in the cross sectional 
study was 44.0±16.9 (mean±standard deviation). Females 
were predominant (61.8%). Almost all of the patients had addi-
tional allergic diseases, including AR (84.4%) and BA (66.3%). 
The mean sCD93 level in 389 subjects was 132.6±50.0 ng/mL 
(Table 1). 
Changes in serum sCD93 levels with disease 
exacerbation
We classified all the subjects into three groups according to 
the status of allergic disease. In AR, 28.4% and 56.0% of all sub-
jects were classified into eAR and sAR, respectively. 54 sub-
jects (15.5%) did not have AR and were defined as control. In 
CSU, eCSU, and sCSU occupied 4.0% and 13.8%, respectively. 
Almost subjects (82.2%) did not have CSU and were defined as 
control. In BA, 33.6% were controls, and 21.8% and 44.5% were 
classified as eBA and sBA, respectively (Table 2). The serum 
sCD93 levels in eAR cases (n=99, 153.1±58.4 ng/mL, mean± 
standard deviation) were significantly higher than those in 
controls who were never diagnosed with AR (n=54, 132.2±49.0 
ng/mL) or sAR (n=195, 122.3±42.1 ng/mL). Serum sCD93 levels 
in controls and in sAR cases showed no significant difference 
(Fig. 2A). The serum sCD93 levels in eCSU cases (n=14, 169.5± 
42.8 ng/mL) were significantly higher than those in controls 
who were never diagnosed with CSU (n=286, 132.4±51.6 ng/
mL) or sCSU (n=48, 122.8±36.2 ng/mL). Serum sCD93 levels 
in sCSU cases were not significantly different from those of 
Table 1. Clinical Characteristics of Cross Sectional Study Subjects
Characteristics
Value
(mean±standard deviation)
Age (yr) 44.0±16.9
Sex (male:female) 133:215
Co-morbid diseases, n (%)
Allergic rhinitis 294 (84.4)
Bronchial asthma 231 (66.3)
Chronic spontaneous urticaria 62 (17.8)
Food allergy 39 (11.2)
Atopic dermatitis 34 (9.8)
Drug allergy 12 (3.4)
Anaphylaxis 10 (2.9)
Serum sCD93 (μg/mL) 132.6±50.0
Total, n (%) 348 (100)
Table 2. Prevalence of Exacerbated and Stable Allergic Disease
Allergic diseases n (%)
Allergic rhinitis (AR)
Exacerbated AR 99 (28.4)
Stable AR 195 (56.0)
Non-AR (control) 54 (15.5)
Chronic spontaneous urticaria (CSU)
Exacerbated CSU 14 (4.0)
Stable CSU 48 (13.8)
Non-CSU (control) 286 (82.2)
Bronchial asthma (BA)
Exacerbated BA 76 (21.8)
Stable BA 155 (44.5)
Non-BA (control) 117 (33.6)
Total 348 (100)
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controls (Fig. 2B). The serum sCD93 levels in eBA cases (n=76, 
146.6±61.4 ng/mL) were significantly higher than those in 
controls who were never diagnosed with BA (n=117, 133.0± 
44.5 ng/mL) or sBA (n=155, 125.4±46.5 ng/mL). Serum sCD93 
levels in sBA cases were similar to those in controls (Fig. 2C). 
Serum sCD93 levels were higher in patients with exacerbated 
allergic diseases than in those whose diseases were stable.
When we selected pure allergic disease and pure control 
group, the results are not far distinct. Only 2 patients who had 
neither AR, BA, nor CSU were included in the pure control 
group (sCD93 level=170.0±28.8). In patients in AR who had nei-
ther BA nor CSU, sCD93 levels in sAR (n=47, 113.9±30.9 ng/mL) 
were significantly lower than those in eAR (n=24, 162.1±53.6 
ng/mL). BA showed insignificant results. In patients in CSU 
who had neither AR nor BA, sCD93 levels in sCSU (n=14, 115.5± 
34.2 ng/mL) was lower than those in eAR (n=5, 154.6±38.3 ng/
mL), without statistical significance (Supplementary Fig. 1, 
only online).
The relationship between serum sCD93 level and 
other laboratory findings
In Pearson’s correlation analysis, there was no significant cor-
relation between sCD93 levels and sputum eosinophil, spu-
tum neutrophil, or serum eosinophil counts or FEV1, and FEV1/ 
FVC. Although blood neutrophils showed statistically signifi-
cant p values (=0.039), Pearson’s coefficients were close to zero 
(=-0.11) (data not shown). 
Serum sCD93 levels according to ICS dose
We analyzed serum sCD93 levels in BA patients according to 
ICS dose. We excluded eAR and eCSU patients to eliminate 
confounding factors. The serum sCD93 levels in non-ICS us-
ers with BA (n=28, 161.4±53.1 ng/mL, mean±standard devia-
tion) were significantly higher than those in healthy controls 
who had never been diagnosed with BA (n=68, 112.2±30.8 ng/
mL), low-dose ICS users (n=45, 125.7±42.0 ng/mL), and me-
dium-dose ICS users (n=62, 113.5±35.5 ng/mL). The serum 
sCD93 levels in high dose ICS users (n=8, 72.2±20.6 ng/mL) 
were significantly lower than those in others. The serum sCD93 
levels in the controls, low-dose ICS users, and medium-dose 
ICS users were not significantly different (Fig. 3).
Changes in the serum sCD93 levels of steroid-naïve 
patients after ICS treatment 
In the cohort study, we analyzed the levels serum sCD93 seri-
ally in 14 steroid-naïve patients with BA who required ICS treat-
ment. The mean patient age was 38.9±14.0 (mean±standard 
deviation) years. Females were predominant (64.3%). Almost 
patients had AR (78.6%). The mean value of sputum eosino-
phils (%) increased (16.3±19.8%), and the mean value of FEV1 
showed a modest decrease (80.0±33.3%) following ICS treat-
ment (Table 3). 
The baseline serum sCD93 levels (ng/mL) in steroid-naïve 
BA patients (n=14, 195.1±72.7, mean±standard deviation) sig-
nificantly decreased after 4 weeks of ICS use (n=12, 134.4±42.8) 
and 8 weeks of ICS use (n=6, 100.7±13.4) (p<0.05). Although 
the serum sCD93 levels at 8 week of treatment were lower than 
those at 4 weeks, this difference was not statistically significant 
(Fig. 4). 
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Fig. 2. Changes in serum sCD93 levels in patients with AR (A), CSU (B), and BA (C) and disease exacerbation. The data are shown as the mean±standard 
error of the mean in the graph. *p<0.05. AR, allergic rhinitis; sAR, stable AR; eAR, exacerbated AR; CSU, chronic idiopathic urticaria; sCSU, stable CSU; 
eCSU, exacerbated CSU; BA, bronchial asthma; sBA, stable BA; eBA, exacerbated BA; sCD93, soluble CD93.
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Fig. 3. Serum sCD93 levels according to ICS dose. The data are shown as 
the mean±standard error of the mean in the graph. *p<0.05 compared to 
the other groups. ICS, inhaled corticosteroids; BA, bronchial asthma; Con-
trol, healthy control without BA; None, non-ICS-users with BA; Low, low-
dose ICS users; Med, medium-dose ICS users; High, high-dose ICS users; 
sCD93, soluble CD93.
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DISCUSSION
Our cross sectional study suggested that the serum sCD93 lev-
els in patients with exacerbated allergic diseases (AR, CSU, 
and BA) are higher than in those with stable diseases. Fur-
thermore, we confirmed that ICS doses used in patients with 
BA were inversely correlated with serum sCD93 levels. We 
then hypothesized that sCD93 levels could be affected by ICS 
use. In a cohort study used to confirm this hypothesis, we 
found that sCD93 levels significantly decreased after ICS treat-
ment. This suggested that serum sCD93 might be worth fur-
ther study as a potential novel diagnostic and therapeutic mark-
er for allergic disease, especially asthma.
CD93 is both a regulator and indicator of inflammation in 
various inflammatory diseases, including peritonitis, SLE, and 
RA.11,12,19 In addition, several studies have revealed that CD93 
is associated with inflammation and immunity in heart disease 
and cancer.20,21 Only two previous study assessed CD93 levels 
in asthmatic patients.22,23 Baines, et al.22 showed that CD93 
mRNA levels were correlated with neutrophilia in sputum sam-
ples of asthma patients on a low antioxidant diet (p=0.04). How-
ever, CD93 was evaluated in sputum rather than serum in this 
previous study, the number of patients was small (n=10), and 
asthma severity and other clinical conditions were not evalu-
ated. Sigari, et al.23 showed the role of sCD93 as a novel bio-
marker in asthma exacerbation; however, the effects of anti-
inflammatory drugs were not considered. We have clarified 
the roles of sCD93 in asthma, and for the first time, in various 
allergic diseases, including AR and CSU. 
The prevalence of allergic diseases is increasing worldwide, 
and useful biomarkers that can easily be applied to clinical 
practice are insufficient. Although there are several methods 
to obtain airway samples, including collecting sputum and 
exhaled air, there are few biomarkers for BA that can be easily 
assessed in clinics. In AR, the available diagnostic tools, rhi-
noscopy and allergic skin test, are expensive, time consuming, 
and invasive. CSU can be defined only by symptoms and clin-
ical manifestations. This study revealed that serum sCD93 
might serve as a novel biomarker for these allergic diseases. 
This study revealed a correlation between sCD93 levels and 
ICS dose in patients. This result is in agreement with a previ-
ous study, where an inverse correlation was observed between 
CD93 expression and prednisone dose in SLE patients.12 How-
ever, the lower levels of serum sCD93 in high-dose ICS users 
than healthy controls who have never diagnosed as BA should 
be further studied. 
The serum sCD93 levels in patients with stable allergic dis-
eases were similar to those in healthy controls without allergic 
disease. In contrast, we found that steroid-naïve patients who 
were diagnosed with BA for the first time at this visit showed 
higher serum sCD93 levels than healthy controls who were 
never diagnosed with BA. Therefore, we suspect that the med-
ications, including not only steroids but also anti-histamines, 
that the patients took to control their symptoms affected se-
rum sCD93 levels. These effects should be studied further.
We have some limitations. The cross sectional study was an 
observational study, so we could not determine whether the 
medication reduced the serum sCD93 levels. Although we 
conducted a cohort study to address this possibility, it includ-
ed too few steroid-naïve subjects with BA. However, this small 
number of subjects revealed significantly decreasing sCD93 
levels over 8 weeks of treatment. This study was designed to 
evaluate the potential for sCD93 to serve as a diagnostic and 
therapeutic marker for asthma. We did not elucidate the under-
lying mechanism or determine whether sCD93 or ICS usage 
was the cause or effect of this phenomenon. We propose that 
Table 3. Clinical Characteristics and Laboratory Findings of Cohort Study 
Subjects
Characteristics Value (mean±standard deviation)
Age (yr) 38.9±14.0
Sex (male:female) 5:9
Co-morbid diseases, n (%)
Allergic rhinitis 11 (78.6)
Laboratory findings 
Blood eosinophil (/μL) 287.6±199.8
Blood neutrophil (/μL) 4000.7±1238.0
Sputum eosinophil (%) 16.3±19.8
Sputum neutrophil (%) 61.2±21.0
FEV1 (% predicted) 80.0±33.3
FEV1/FVC (%) 88.3±31.2
Serum sCD93 (μg/mL)
Baseline (n=51) 195.1±72.7
4 wk f/u (n=49) 134.4±42.9
8 wk f/u (n=8) 100.7±32.7
Total, n (%) 14 (100)
sCD93, soluble CD93; FEV1, forced expiratory volume in one second; FVC, 
forced vital capacity.
Fig. 4. Serial serum sCD93 levels during treatment with ICS in steroid-naïve 
patients with BA. *p<0.05 between groups. ICS, inhaled corticosteroids; BA, 
bronchial asthma; sCD93, soluble CD93.
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there might be a significant correlation between sCD93 levels 
and inflammation in asthmatic patients, as well as in other in-
flammatory diseases. We are not sure whether sCD93 plays a 
significant role in the T helper 2 pathway, which is considered 
important in allergic diseases. The sCD93 might be involved 
in inflammation irrelevant to T helper pathway. In the present 
situation, with very few validated serologic biomarkers for al-
lergic diseases, especially asthma, sCD93 may prove to be a 
useful biomarker in the evaluation of allergic disease. Last, the 
therapeutic protocols in the cohort study varied. The duration 
and dose of ICS was determined by doctor’s judgment. An ob-
jective and fair criteria for therapeutic protocol should be ap-
plied. In addition, comparisons of sCD93 levels according to 
the status of asthma control might be more informative.
This is the first study to evaluate CD93 as a biomarker for 
various allergic diseases according to exacerbation and treat-
ment. Although further studies are needed to determine the 
mechanisms by which sCD93 participates in the development 
and progression of allergic diseases, the studies presented here 
validate the use of sCD93 as a novel biomarker in allergic dis-
eases, especially asthma. 
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